Retrospective data from the phase II EXPERT trial, which involved patients with high-risk, locally advanced rectal cancer who received neoadjuvant therapy with capecitabine and oxaliplatin with chemoradiotherapy with or without cetuximab, showed a 4.3% prevalence of HER2 overexpression. The gene discussed is ERBB2; the disease is rectal cancer.